{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-036001","form_type":"8-K","ticker":"VVOS","cik":"0001716166","company_name":"Vivos Therapeutics, Inc.","filed_at":"2022-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.856987+00:00","generated_at":"2026-06-21T01:49:36.884269+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vivos Therapeutics reports Q2/Q3 2022 revenue $4.2M each; appliance units up 28% and 20% YoY","bullets":["Q2 revenue $4.2M, Q3 revenue $4.2M; net income not disclosed due to revenue recognition policy change.","Appliance arches sold: 3,321 (Q2, +28% YoY) and 3,057 (Q3, +20% YoY).","Gross margin fell to 62% (Q2) and 59% (Q3) from 81% and 70% in prior year periods.","Cash and equivalents $6.7M at Sept 30, 2022; company targeting positive cash flow in 12-18 months.","Operational highlights include TGA clearances for oral appliances in Australia and strategic billing partnership with Nexus Dental."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-036001","json":"https://secwatch.observer/filing/0001493152-22-036001.json","markdown":"https://secwatch.observer/filing/0001493152-22-036001.md","text":"https://secwatch.observer/filing/0001493152-22-036001.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716166/000149315222036001/0001493152-22-036001-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716166/000149315222036001/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T01:49:36.884269+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"165e951f54ee0eae375d8460bd77445359974fd7","claim":"Vivos Therapeutics, Inc. reported the second quarter of 2022 results: revenue $4.2 million.","evidence_excerpt":"Revenue was $4.2 million for the second quarter of 2022 and $7.8 million for the six months ended June 30, 2022, compared to $4.5 million and $7.9 million for the three and six months ended June 30, 2021, respectively, which in part reflects a deferral of a portion of revenue into future periods under Vivos’ new revenue recognition policies;","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315222036001/0001493152-22-036001-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter of 2022"},{"label":"Revenue","value":"$4.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"2422201cfabed89255be6d07bd8445057f1ca9ac","claim":"Vivos Therapeutics, Inc. reported the third quarter of 2022 results: revenue $4.2 million.","evidence_excerpt":"Revenue was $4.2 million for the third quarter of 2022 and $12.1 million for the nine months ended September 30, 2022, compared to $4.5 million and $12.5 million for the three and nine months ended September 30, 2021, respectively, which similarly in part reflects a deferral of a portion of revenue into future periods under Vivos’ new revenue recognition policies;","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315222036001/0001493152-22-036001-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2022"},{"label":"Revenue","value":"$4.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}